Canagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, attenuates pancreatic fibrosis in chronic pancreatitis through the AMPK–OPG–CTGF axis
Pancreatology · 2026-08 · 26 (5) · 686-698
DOI: 10.1016/j.pan.2026.05.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pancreatology, 2026-08. Verfasst von Akihisa Adachi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, 467-8601, Japan. Hauptthemen laut MEDLINE: Pancreatitis, Chronic, Canagliflozin, Connective Tissue Growth Factor, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Manpei Suzuki International Prize for Diabetes Research, Terumo Foundation for Life Sciences and Arts.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, 467-8601, Japan.
- Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya, 467-8601, Japan.
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, 467-8601, Japan. Electronic address: akihisa@med.nagoya-cu.ac.jp.
Förderung
- Japan Society for the Promotion of Science
- Manpei Suzuki International Prize for Diabetes Research
- Terumo Foundation for Life Sciences and Arts
- Mitsubishi Tanabe Pharma Corporation
Zitieren
APA
Adachi, A., Kato, H., Kato, A., Yoshida, M., Hori, Y., Toyohara, T., Oda, K., Kito, Y., Urakabe, K., Mori, T., Takahashi, S., & Kataoka, H. (2026). Canagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, attenuates pancreatic fibrosis in chronic pancreatitis through the AMPK–OPG–CTGF axis. Pancreatology, 26(5), 686-698. https://doi.org/10.1016/j.pan.2026.05.006
Vancouver
Adachi A, Kato H, Kato A, Yoshida M, Hori Y, Toyohara T, et al. Canagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, attenuates pancreatic fibrosis in chronic pancreatitis through the AMPK–OPG–CTGF axis. Pancreatology. 2026;26(5):686-698. doi:10.1016/j.pan.2026.05.006
BibTeX
@article{Adachi2026,
author = {Adachi, Akihisa and Kato, Hiroyuki and Kato, Akihisa and Yoshida, Michihiro and Hori, Yasuki and Toyohara, Tadashi and Oda, Kayoko and Kito, Yusuke and Urakabe, Kenji and Mori, Toshitaka and Takahashi, Satoru and Kataoka, Hiromi},
title = {Canagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, attenuates pancreatic fibrosis in chronic pancreatitis through the AMPK–OPG–CTGF axis},
journal = {Pancreatology},
year = {2026},
volume = {26},
number = {5},
pages = {686--698},
doi = {10.1016/j.pan.2026.05.006}
}
EUVIMED